New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 26, 2014
07:49 EDTEXELExelixis price target lowered to $9 from $11 at Stifel
Stifel cut its price target on Exelixis after the company announced that a committee had determined that its Phase III trial should continue based on lack of sufficient survival benefit to halt the trial,. The firm had expected the trial to be stopped early due to efficacy. Stifel notes that trials of competing drugs have been stopped early due to favorable results. However, it thinks the final results of Exelixis' trial could still be positive and keeps a Buy rating on the shares.
News For EXEL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2015
10:34 EDTEXELOptions with decreasing implied volatility
Subscribe for More Information
July 23, 2015
20:10 EDTEXELExelixis 25M share Secondary priced at $5.40
The size of the deal was raised to 25M shares from 20M shares. Cowen, William Blair and Stifel acted as joint book running managers for the offering.
10:08 EDTEXELOptions with decreasing implied volatility
Subscribe for More Information
July 22, 2015
10:15 EDTEXELOptions with decreasing implied volatility
Subscribe for More Information
09:07 EDTEXELOn The Fly: Pre-market Movers
Subscribe for More Information
July 21, 2015
19:00 EDTEXELOn The Fly: After Hours Movers
Subscribe for More Information
16:02 EDTEXELExelixis files to sell 20M shares of common stock
Cowen and Company, William Blair and Stifel are acting as bookrunners for the offering.
10:24 EDTEXELOptions with decreasing implied volatility
Subscribe for More Information
July 20, 2015
13:39 EDTEXELExelixis price target raised to $6 from $2.50 at Piper Jaffray
Subscribe for More Information
12:57 EDTEXELExelixis upgraded to Outperform from Market Perform at Cowen
Subscribe for More Information
12:08 EDTEXELOn The Fly: Top stock stories at midday
Stocks on Wall Street were slightly higher at midday in the first trading day of a week that will be light on domestic economic data but heavy on earnings reports. Investors will be receiving profit reports from about 25% of the companies on the S&P 500 this week, making this the highest volume earnings week of this season. ECONOMIC EVENTS: In the U.S., no major data was released. In Europe, Greece reopened its banks three weeks after closing as the country worked out another bailout agreement. The country announced it has started the process of paying off its creditors, including the European Central Bank and the International Monetary Fund, with a bridge loan it just received. COMPANY NEWS: Lockheed Martin (LMT) agreed to buy the Sikorsky Aircraft business from United Technologies (UTX) for $9B, noting the price is "effectively reduced" to $7.1B after taking into account tax benefits resulting from the transaction. Shares of Lockheed, which also reported better than expected second quarter results and increased its fiscal year guidance, gained nearly 2% after the Sikorsky announcement and saying it will conduct a strategic review of its government IT infrastructure services business and technical services business... Shares of Morgan Stanley (MS) shares were little changed near noon after the bank reported earnings and revenue, excluding certain adjustments, that topped analysts' consensus forecasts... SunEdison (SUNE) announced a deal to acquire Vivint Solar (VSLR) for approximately $2.2B, payable in a combination of cash, shares of SunEdison common stock and SunEdison convertible notes. In connection with the proposed acquisition of Vivint Solar, SunEdison has entered into a definitive purchase agreement with a subsidiary of TerraForm Power (TERP) which, concurrently with the completion of SunEdison's acquisition of Vivint, will acquire Vivint Solar's rooftop solar portfolio, consisting of 523 MW expected to be installed by year-end 2015, for $922M in cash. Shares of Vivint rose 44% following the announcement, while SunEdison's stock gained 4% and TerraForm dropped 3%. Fellow residential solar installer SolarCity (SCTY), which is backed by Tesla's (TSLA) Elon Musk, rose 7% following the deal in the space. MAJOR MOVERS: Among the notable gainers was Exelixis (EXEL), which rallied 43% after the company reported that a study of cabozantinib in metastatic renal cell carcinoma met its primary endpoint of significant improvement in progression-free survival. The shares were indicated to rise even more in early pre-market trading, but lost some of their gains after Bristol-Myers (BMY) announced that its Opdivo study was stopped early after showing superior overall survival in a Phase 3 study of previously treated patients with advanced or metastatic renal cell carcinoma. Bristol-Myers rose a bit less than 1% to trade near $70 per share after its own announcement. Also higher was PayPal (PYPL), which gained more than 5.5% in its first day of trading after being spun out of eBay (EBAY). Meanwhile, eBay shares rose over 2%. Cal-Maine Foods (CALM) dropped 8% after posting lower than expected sales and profits in its fourth quarter and warning that while it should have an adequate supply of its primary feed ingredients, the company expects that prices will be "volatile" in the year ahead. Also lower were shares of several gold miners, including Barrick Gold (ABX) and Newmont Mining (NEM), which each fell about 11%, as gold prices declined about 2% near midday. INDEXES: Near midday, the Dow was up 31.66, or 0.18%, to 18,118.11, the Nasdaq was up 9.81, or 0.19%, to 5,219.96, and the S&P 500 was up 2.82, or 0.13%, to 2,129.46.
10:13 EDTEXELOptions with decreasing implied volatility
Subscribe for More Information
10:05 EDTEXELHigh option volume stocks
09:37 EDTEXELExelixis surges, levels to watch
Subscribe for More Information
09:22 EDTEXELOn The Fly: Pre-market Movers
Subscribe for More Information
08:28 EDTEXELExelixis off highs, but still up 34% after Bristol-Myers data
Subscribe for More Information
07:23 EDTEXELExelixis to host conference call
Subscribe for More Information
07:03 EDTEXELExelixis says METEOR top-line results 'positive'
Exelixis announced positive top-line results from the primary analysis of METEOR, the phase 3 pivotal trial comparing cabozantinib to everolimus in 658 patients with metastatic renal cell carcinoma, or RCC, who have experienced disease progression following treatment with a VEGF receptor tyrosine kinase inhibitor, TKI. The trial met its primary endpoint of demonstrating a statistically significant increase in progression-free survival in the first 375 randomized patients as determined by an independent radiology committee. METEORís primary analysis included a review of serious adverse event data. Based on this analysis, the frequency of SAEs of any Grade regardless of causality was approximately balanced between study arms. The rate of treatment discontinuation due to adverse events was low in both study arms.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use